$0.280
-0.017 (-6.23%)At close
HRTX News
HRTX Events
Largest Indicative Borrow Rate Increases Among Liquid Option Names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Stellantis NV (STLA) 4.34% +3.40, PureCycle Technologies (PCT) 46.54% +3.01, GRANITESHARES 2X LONG MU DAILY ETF (MULL) 16.80% +2.10, Draganfly (DPRO) 21.36% +0.88, Tidal Trust II (IRE) 22.37% +0.87, Ondas Holdings (ONDS) 3.80% +0.81, Inovio (INO) 37.57% +0.69, MSOX ETF (MSOX) 10.04% +0.50, Heron Therapeutics (HRTX) 1.76% +0.49, and SPDR S&P Bank (KBE) 3.34% +0.49.
Heron Therapeutics Enters Multi-Product Development License Agreement with Long Grove
In a regulatory filing, the company stated, "On September 23, 2026, Heron Therapeutics entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals and Capstone Development Services Company, a Delaware limited liability company which provided for, among other things, the grant by Long Grove to the company of an exclusive (as to the licensed patents), sublicensable license to import, distribute, sell and market certain products in the United States, including its territories, commonwealths and possessions, and a non-exclusive license to manufacture such products worldwide for sale in the Territory and certain obligations to collaborate on developing and commercializing such products. Capstone is a party to the License Agreement solely to provide certain exclusivity covenants and backstop obligations. Under the License Agreement, the company shall pay to Long Grove certain regulatory milestone payments, sales-based milestone payments, and royalty payments and be reimbursed for certain expenses. The License Agreement has an initial term of ten years following the first commercial sale of any product, with automatic two-year renewal terms, and may be terminated by either Party upon the occurrence of certain conditions customary for agreements of this type."
Significant Increases in Indicative Borrow Rates for Liquid Options
Latest data shows the largest indicative borrow rate increases among liquid option names include: GraniteShares 2x Long INTC Daily ETF (INTW) 22.21% +3.70, Starfighters Space, Inc. (FJET) 12.29% +1.60, Tradr 2X Short NBIS Daily ETF (NBIZ) 52.82% +1.52, Yellowstone Midco Holdings Ii, Llc (YSS) 6.32% +1.26, GRANITESHARES 2X LONG DELL DAILY ETF (DLLL) 8.97% +1.18, T-REX 2X Long BMNR Daily Target ETF (BMNU) 28.35% +0.93, Heron Therapeutics (HRTX) 2.03% +0.61, Defiance 1.75x MSTR ETF (MSTX) 21.31% +0.44, Tradr 2X Long QBTS Daily ETF (QBTX) 26.89% +0.43, and Draganfly (DPRO) 15.20% +0.35.
Heron Therapeutics Loses Patent Litigation, Plans to Appeal
Heron Therapeutics announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India and Slayback Pharma, with respect to Cinvanti injectable emulsion, holding that the asserted claims of company's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to Cinvanti injectable emulsion or Aponvie injectable emulsion. Heron intends to appeal the decision to the United States Court of Appeals for the Federal Circuit, a court that specializes in patent disputes.
Heron Q1 Revenue at $34.71M, Below Consensus
Reports Q1 revenue $34.71M, consensus $36.72M. "Despite typical first-quarter seasonality and unusual weather-related disruption early in the quarter, we saw a clear recovery in February and March," said Craig Collard, Chief Executive Officer of Heron. "Our Acute Care franchise continues to perform with strong year-over-year growth, and we remain confident in our full-year framework as deferred elective procedures return and our commercial catalysts such as IGNITE 2.0, unique J-Codes, and planned sales force expansion for the Acute Care franchise continue to build through 2026."
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.